Loading…
Qiagen N.V. is projected to rise to $39.59 by 2027, a +10% move from its current price of $36.13. QGEN is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $35.56 | $36.14 | $36.72 | +0.01% |
| May 30 | $35.33 | $36.14 | $36.97 | +0.03% |
| May 31 | $35.15 | $36.15 | $37.16 | +0.04% |
| Jun 1 | $35.01 | $36.15 | $37.33 | +0.06% |
| Jun 2 | $34.88 | $36.16 | $37.48 | +0.07% |
| Jun 3 | $34.77 | $36.16 | $37.61 | +0.08% |
| Jun 4 | $34.66 | $36.17 | $37.74 | +0.10% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $34.66 | $36.17 | $37.74 | +0.10% |
| Week 2 | $34.09 | $36.20 | $38.44 | +0.20% |
| Week 3 | $33.67 | $36.24 | $39.00 | +0.30% |
| Week 4 | $33.32 | $36.27 | $39.49 | +0.40% |
| Week 5 | $33.02 | $36.31 | $39.93 | +0.50% |
| Week 6 | $32.75 | $36.35 | $40.33 | +0.60% |
| Week 7 | $32.51 | $36.38 | $40.71 | +0.70% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Qiagen N.V. operates in the healthcare sector, providing sample-to-insight solutions that transform biological samples into molecular insights worldwide. Its portfolio includes sample technology consumables such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies.
It also offers secondary sample technology consumables, purification kits for nucleic acids, and instruments for nucleic acid purification, quality control, and accessories. The company provides Immune response consumables, oncology and reproductive health assays, genomic variant analysis, and sample-to-insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes and integrated PCR testing. Qiagen offers research PCR consumables, DNA methylation analysis, bioinformatics solutions, and sequence-based assays, including forensic genetic genealogy services, software-as-a-service, and serves molecular diagnostics and life sciences sectors.
The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
Qiagen N.V. (QGEN) is a healthcare company with a broad portfolio spanning sample to insight solutions, assays, instruments, and software for molecular diagnostics and life sciences. The current price is $35.17 per share and the market cap stands at $7.25B, with a market ranking of 1090.
These figures place Qiagen as a mid-cap player within the technical and diagnostic tools landscape. The near-term outlook and longer-term price path are defined by the forecasted averages and ranges across multiple years.
A major floor 23.1% below — a decisive break under it would weaken the trend.
The nearest floor, 9.7% below — buyers have tended to step in here.
The nearest ceiling, 15.3% above — a clean break opens room to run.
A major ceiling 54.1% above — clearing it would confirm fresh momentum.
Key QGEN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of QGEN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $35.36 | Buy | $35.34 | Buy |
| MA 10 | $34.38 | Buy | $34.86 | Buy |
| MA 20 | $34.08 | Buy | $35.13 | Buy |
| MA 50 | $37.69 | Sell | $37.76 | Sell |
| MA 100 | $43.31 | Sell | $40.83 | Sell |
| MA 200 | $44.91 | Sell | $43.11 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 52.83 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 179.15 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.57 | Buy |
| ROC (12) | 9.35 | Buy |
| Bollinger %B (20,2) | 1.05 | Sell |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | -0.55 | Sell |
| Awesome (5,34) | -1.12 | Sell |
| Ultimate (7,14,28) | 76.45 | Sell |
| Momentum (10) | 2.43 | Buy |
| Aroon Osc (25) | -56.00 | Sell |
| Hull MA (9) | 35.98 | Buy |
| ADX (14) | 26.12 | Buy |
| ATR (14) | 0.60 | Info |
Technically, the near term shows neutral momentum with RSI14 at 50. The stock trades around the 50-day moving average of $37.89 and the 200-day moving average at $45.03, suggesting a broad consolidation relative to longer-term trends. Support is identified at $32.63 and resistance at $41.91, framing a 30-day range from $31.54 to $39.22.
The setup indicates a cautious stance in the 30-day window, with volatility reflected in the 30-day trading range and a neutral sentiment backdrop.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $32.63 | $36.13 | $47.07 | 0% | Neutral | |
| $32.34 | $39.59 | $50.73 | +10% | Neutral | |
| $32.02 | $39.92 | $52.48 | +10% | Neutral | |
| $32.89 | $41.61 | $55.85 | +15% | Neutral | |
| $34.90 | $44.75 | $61.12 | +24% | Bullish | |
| $40.56 | $52.64 | $73.02 | +46% | Bullish | |
| $43.73 | $57.38 | $80.71 | +59% | Bullish | |
| $44.95 | $59.61 | $84.92 | +65% | Bullish | |
| $46.73 | $62.57 | $90.20 | +73% | Bullish | |
| $46.71 | $63.13 | $92.01 | +75% | Bullish | |
| $64.78 | $91.30 | $139.41 | +153% | Bullish | |
| $105.18 | $158.97 | $260.12 | +340% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $32.63 | $36.13 | $42.43 | +0.00% |
| June 2026 | $31.75 | $37.04 | $44.05 | +2.52% |
| July 2026 | $31.19 | $36.60 | $43.93 | -1.20% |
| August 2026 | $30.92 | $36.44 | $44.06 | -0.43% |
| September 2026 | $31.58 | $37.35 | $45.43 | +2.50% |
| October 2026 | $31.78 | $37.72 | $46.13 | +0.99% |
| November 2026 | $31.43 | $37.42 | $45.98 | -0.79% |
| December 2026 | $31.95 | $38.14 | $47.07 | +1.92% |
Click any year to see its month-by-month QGEN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect QGEN to range from $32.63 to $47.07 through 2026. The $36.13 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The QGEN price prediction for 2027 points to an average of $39.59 (low $32.34, high $50.73) — a potential gain of +10% on today's $36.13. A consolidation phase looks the most probable path here.
In 2028, QGEN is projected to trade between $32.02 and $52.48, averaging $39.92 — a potential gain of +10% from today's $36.13. That is up +1% on the projected 2027 average. Price action looks broadly range-bound.
Qiagen N.V.'s 2029 outlook centres on $41.61, within a $32.89 to $55.85 range. That is up +4% on the projected 2028 average. That marks a +15% change versus current levels. A consolidation phase looks the most probable path here.
By 2030, QGEN could reach as high as $61.12, with a base case around $44.75 and support toward $34.90 — roughly +24% from $36.13. Momentum favours further upside here.
Expect QGEN to range from $40.56 to $73.02 through 2031. The $52.64 average target implies a +46% move from current prices. That is up +18% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The QGEN price prediction for 2032 points to an average of $57.38 (low $43.73, high $80.71) — a potential gain of +59% on today's $36.13. Momentum favours further upside here.
In 2033, QGEN is projected to trade between $44.95 and $84.92, averaging $59.61 — a potential gain of +65% from today's $36.13. That is up +4% on the projected 2032 average. Buyers look set to stay in control over this stretch.
Qiagen N.V.'s 2034 outlook centres on $62.57, within a $46.73 to $90.20 range. That is up +5% on the projected 2033 average. That marks a +73% change versus current levels. Momentum favours further upside here.
By 2035, QGEN could reach as high as $92.01, with a base case around $63.13 and support toward $46.71 — roughly +75% from $36.13. Buyers look set to stay in control over this stretch.
Expect QGEN to range from $64.78 to $139.41 through 2040. The $91.30 average target implies a +153% move from current prices. That is up +45% on the projected 2035 average. Momentum favours further upside here.
The QGEN price prediction for 2050 points to an average of $158.97 (low $105.18, high $260.12) — a potential gain of +340% on today's $36.13. Buyers look set to stay in control over this stretch.
Investing $1,000 in QGEN today (≈ 27.67783 QGEN) could be worth
$4,400.06
+$3,400.06 (+340%) by 2050 · US Dollar
Based on the average projected QGEN price of $158.97 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in QGENwould be worth at today's price.
$1,000 invested in QGEN on May 27, 2025 (≈ 22.805018 QGEN) would be worth
$823.95
-$176.05 (-17.6%) today · 0.82× · US Dollar
Based on a QGEN entry price of $43.85 vs. today's $36.13.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $35.09 | $1,029.64 | +3.0% |
| 1 month ago | $38.09 | $948.54 | -5.1% |
| 3 months ago | $49.08 | $736.15 | -26.4% |
| 6 months ago | $47.75 | $756.65 | -24.3% |
| 1 year ago | $43.85 | $823.95 | -17.6% |
| All time (5.0y) ago | $49.12 | $735.5 | -26.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our QGEN forecast.
Our base-case forecast reaches $72.00 around 2040.
Implied market cap at $72.00: $14.85B
The multi-year forecast paints a growth path with increasing average prices and rising ROI from 2026 onward. In 2026 the avg price is $35.17 with a 0% ROI and NEUTRAL sentiment. Rising momentum appears from 2030 onward, where the avg is $43.27 with a 23% ROI and a bullish tone, followed by continued gains through 2035 (avg $61.05, ROI 73.6%) and 2040 (avg $87.43, ROI 148.6%).
By 2050, the avg price is projected at $153.02 with a 335.1% ROI and a bullish sentiment, supported by a max forecast of $250.41. These figures imply meaningful upside over the long term, though they come with uncertainty and are not guarantees. The path highlights broad strength in the later years, alongside potential pullbacks and shifting risk factors that could influence outcomes.
Tap a question to reveal the answer.
In 2030, the forecasted avg price is $43.27 with a 23% ROI and a bullish sentiment, with a min of $33.74 and a max of $59.12.
The 2026 forecast shows an avg price of $35.17 with 0% ROI and NEUTRAL sentiment, reflecting a flat near-term stance.
Yes. By 2040 the avg is $87.43 with a 148.6% ROI, and by 2050 the avg is $153.02 with a 335.1% ROI and a bullish sentiment, with a max of $250.41.
The current price is $35.17 and the market cap is $7.25B.
For 2040, the avg is $87.43 with a 148.6% ROI; for 2050, the avg is $153.02 with a 335.1% ROI and a bullish sentiment, with a max of $250.41.
Qiagen N.V. Community Discussion
0Share your Qiagen N.V. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.